

# Agendia Data Analysis Pipeline Tool (ADAPT-CE)

### **User Guide**

For use only in combination with the MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit





EM-002-v4 (2023 December)



### Contents

Introduction	3
System Requirements	3
ADAPT-CE Requirements	3
Agendia Service Connector Requirements	3
Initial Setup	4
Creating an ADAPT-CE Account	4
Installing the Agendia Service Connector	5
Customizing ADAPT-CE Reports	6
Using ADAPT-CE	7
Uploading FASTQ Files	7
Analyzing Data	8
Downloading Reports	8
ADAPT-CE Reports	9
Technical Report	9
I. Specimen File ID	9
2. Testing Lab Use Only	9
3. Run Information	10
4. Detailed QC information	10
5. MammaPrint Test Result	11
6. BluePrint Test Result	11
Explanation of Results (EoR)	12
I. Specimen File ID	12
2. Summary of Individual Test Results	13
3. Predicted Result without Systemic Treatment	13
4. Data from the MINDACT Trial for Concordant Classification	13
with Systemic Treatment	
5. Data from the MINDACT Trial for Discordant Classification	13
6. Clinical Risk Assessment Table	14
7. BluePrint Molecular Subtyping Results	14
Troubleshooting	15
Miscellaneous	16
Security	16
Browser Session Timeout and Symbols	16
Assistance and References	17

ADAPT-CE User Guide

### Introduction

This User Guide covers important information on how to use the Agendia Data Analysis Pipeline Tool (ADAPT-CE), which is a high-performance and security-compliant cloud-based genomics analysis platform. ADAPT-CE is intended to be used in combination with the MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit (MammaPrint BluePrint Kit). ADAPT-CE delivers integrated analysis and results reporting of samples processed with the MammaPrint BluePrint Kit.

This User Guide will provide step-by-step instructions to create an account, install a secure file connector, upload, and analyze de-identified patient data in a secure environment, and retrieve test results.

Prior to starting, review all instructions in this User Guide. If you still have questions after reading this User Guide, please contact NGS.support@agendia.com for assistance.

### System Requirements

#### ADAPT-CE REQUIREMENTS

ADAPT-CE is a secure cloud-based system which can be accessed through the browsers listed below.

Browser	Supported Version	Operating System
Google Chrome	Most recent stable version	Windows, Mac, and Linux
Mozilla Firefox	Most recent stable version	Windows, Mac, and Linux

For proper functioning of ADAPT-CE, ensure that cookies are enabled in the browser.

#### AGENDIA SERVICE CONNECTOR REQUIREMENTS

The Agendia Service Connector is a secure file transfer protocol connector that will need to be installed to upload data to ADAPT-CE.

The Agendia Service Connector can be installed in Windows, Mac and Linux environments.

For proper functioning of the connector,

- Ensure that your Internet connection is 1.5 Mbps or faster.
- Ensure the outbound ports TCP443 (SSL) and TCP22 (SSH) are open in firewalls that may be present.

**CAUTION:** Users may need administrative privileges on their computers to install the Agendia Service Connector and/or to configure firewalls. Consult with your IT Department for assistance.





### **Initial Setup**

#### CREATING AN ADAPT-CE ACCOUNT

- 1. An automated registration email is sent from Illumina ICA which provides a link to the ADAPT-CE registration portal.
- 2. Open the link in the email to go to the ADAPT-CE registration portal.
- 3. Enter the requested information,
  - a. First Name & Last Name for your account
  - b. To adhere to security requirements, the chosen password must include at least one of the following characters: ! . @ # \$ % ^ & \*-
- 4. Review Terms and Conditions and click the check box to Accept.
- **5.** Once you click on "Register", ADAPT-CE will have registered your account details.
- **6.** The page will now refresh with the login screen. Enter your credentials to access to your newly registered account.

Settings				2	6
A REPORT SETTINGS				67	R los
	Choose File the fit choose		E Indude agranate box	-	
	Where a logic is approached, it will be alignifyed where a sport is around		the desiry to be also a spotawise of its	provided where a segment is created	
PERSONAL SETTINGS					10 mm
For same	Deta	final address	demo una liñacencia com		
Last name	law		The factor automation		
Name resourced		Mobile phone "	+1355125454		
	memory of a charactery, moved pass, particle prior of the following charactery 1, 1 & 4, 5, 5, 5, 6, 5 (				
Balance Space Compared					
	Free year parameter a management				
SITE CONNECTIVITY SETT	30%			6	Statistic Statistics
	Place dor't out an oreand develate information	is the same of the files which all	(in university)	(°	
100	Weaterstein and port (4) 10 P	Pa Com Serve O Pale and			1000
Constant	FASTE_Uploat		First in this failing will be unbested a conversally		
Courses and	Western	Const Maler		6	
AGENDIA			🛓 Darthoard 🛛 📓 Accury	O tampe A testeatore	O may different chair -
AGENDIA			🛆 Datibased 📓 Activity	O second	O rate di Carro (dar -
AGENDIA Settings  Brenott settings			A Darksond Strong	🗘 temp	O ray Laws (Jar -
AGENDIA Settings			🛆 Guellowed 📰 Activity	🗘 testinge	O Hay Land (Jan -
AGENDIA Settings B REPORT SCITINGS	Count fish the design		L Darbourd ■ Astroy	🗘 terrige	O nay di Cany Lar -
Settings	Conset File   to the chosen There are a set such ( ) and the integrated over a region is a result		▲ Charlower ▲ Activity © Inductor argument from Mice reading for the stores, a capability of the stores	lenerative a sport a random	O Hop & Davis Law-
AGENDIA Settings PRPORT SETTINGS	Const Fig. (to the Courses Sector 2 super 2 sector 2		▲ Statistics ▲ Arrive	Discoup Analysis	O Hop & Davis Law-
AGENDIA Settings REPORT SETTINGS FERSONAL SETTINGS Free name 1	Consection for the channess (consection of a space is associated for the channess of the consection of the channess of the cha	Eral addres	L Carlored E Arrey	Comp Antonious	Directo de como como como como como como como com
AGENDIA Sectors Sectors Sectors Sectors AFRESONAL SETTINGS  FRESONAL SETTINGS	Conset Fig. So the choses (40000)	Enalation	Dathart      Dathart     Control of the second	tenten a sport a sease.	O may de bana (der -
AGENDIA     AGENDIA     Settings     Report settings     A PERSONAL SETTINGS     A PERSONAL SETTINGS     Can space     Nap pagender	Const Fig. No the Chapter Miller a sign i activated if and the adaptive singura a second Dense Law	Erral addres	▲ Seattown ■ Arroy	C temp	
AGENDIA     AGENDIA     AGENDIA     AGENTIA      KENDIAL SETTINGS      AFEBOOIAL SETTINGS      ALE AMER      AGENMENT      ALE AMERIC      ALE AMERIC	Chemise File () with the designed of th	Straf abbrea	Deriver	The second secon	O ray & defense (dar-
AGENDIA     Settings     Brevort settings     Arease     Arease     Arease     Settings	Constituting for the changes         Terming           There is a graduable if and the changes of one region is annual         Terming           Dama         Terming           Take         Terming           Take         Terming           Take         Terming	Small address Millelin address *	Dattant     Data     Data	e tory Andrew	O may & there (see -
AGENDIA     Declaration     Agenticat     Settings     Settings     Report settings     Report settings     Report settings     Arease     Knowneen     Knowneen     Knowneen	Construction         Section           Where a sign is calleded, 2 and the interpretation a sign is a second         Section           Construction         Section	Ernal abbrea	Continues     Continues     Control of the second sec	e reng fandeare	
AGENDIA     Settings     AFENORS SETTINGS     FREIORIS SETTINGS     FreeCorts SETTINGS     Non-parameter     Non-parameter     Today revo parameter	Consert (b) to the chances         If the set of the set	Errari antirea Angleia pitorea*	L partnerst La Array		
AGENDIA     Settings     Beroet settings     Freecott settings     Freecott settings     Freecott     Thing may may passed     Thing may may passed	Description from the contrast of the compare a contrast         Contrast from a contrast of the compare a contrast of the compare a contrast of the contrast o	Erraf addres Middle phone*	Deriver		
AGENDIA     Settings     APROFT SETTINGS     Pretries     Pretrie	Constra Fig. No Re choses         Internet           There ages's calibration, C and the interpret of our angular is another         Internet           User         Internet           User         Internet           Second         Internet           User         Internet           Internet of the descents, road (see, summa ore of the following channes 1) (6.4.5 % 1.4.5 -)         Internet           After your present of second tots         NMOS         Please durit just are greatering channeling for planetage	Erral abbres Midde phone *	Dation     Dation		(my)     (monos)     (mon
ACENDIA     Settings     Contings     APSIONAL SETTINGS     APSIONAL SETTINGS     APSIONAL SETTINGS     APSIONAL SETTINGS     Apple semicord     Takiny new parameter     Apple COMMECTIVITY SETT     EXTED Salace	Constitution         Notes           The series 's soluble', if all the integrated over a region is a result         Notes           Dama	Small address Mobile phone * 1: No series of No Tiles which all	Destroyer     Destroyer     According     According		
AGENDIA     Settings     Settings     Report SETING     Report SETI	Constituting for the chapters  Constituting for the chapters  Constituting of the chapters  Con	Errord address Models phone * In the same of Pair file solid and end from balance to search are	Cardinard      Cardinard		
AGENDIA     Actings     Actings     Actings     AFENORS     AFENORS     AFENORS     AFENORS     Afenors     Acting     Acting     Acting     Acting		Errard address Boldela phone* In the space of the State which an in the space of the State which an			



#### INSTALLING THE AGENDIA SERVICE CONNECTOR

To upload data to ADAPT-CE, you will need to download and install the Agendia Service Connector to ensure a secure and robust file transfer protocol.

▲ CAUTION: Please consult with your IT Department before installing any software in your business environment.

In addition, ADAPT-CE connector requires the installation and operation of the program to be on a local drive.

- Log into your ADAPT-CE account at <u>https://ica.illumina.com/ADAPT-CE</u>

   When logging in using some browsers, you may need to click "Sign In" twice.
- **2.** In the ADAPT-CE top menu bar, click on "Settings".
- 3. In the section titled "Site Connectivity Settings", click "New".
- **4.** Enter a unique name for your connector. e.g., "[Site Name] ADAPT-CE Connector".
- 5. Select your Operating System from the drop-down list (Windows, Mac or Linux).

a. If you do not know your computer's Operating System, consult with your IT department for assistance.

**6.** For the "Local folder", provide the Local directory path for the folder containing the relevant FASTQ files that need to be uploaded to ADAPT-CE for analysis.

a. Example: "C:\ADAPT\_Connector\FASTQ Uploads"

- 7. Click "Save" to record the settings.
- **8.** ADAPT-CE will now display an initialization key vital to the installation. Please copy/paste this key to a safe and retrievable location as you will need the key in the next installation step.
- **9.** ADAPT-CE will then open a dialog box allowing you to save the installer for the Agendia Service Connector.
- **10.** Select a local drive location on your computer and save the Agendia Service Connector installer.



🂮 Setup - Agendia Service Connector agendia-1.8.0_4	-		×		
Connection details Please enter the required information		-			
Key eef7c144-c35d-40f9-95a9-6d20c2ec5bd7			0		
			110		
				SITE CONNECTIVITY SETTINGS	
					[
				Validation	
				% currently connected	
< Back	Next >	Ca	ncel	Operating system Windows	



- 11. Once the Service Connector Installer is downloaded, navigate to the location of the saved program and initialize the Installer.
  - a. Follow the instructions in the installer and click "Next" as prompted.
  - b. Select the local drive installation directory.
  - c. Enter or paste the initialization key that was provided by ADAPT-CE from Step 8.
  - d. Installation will now initiate.
  - e. When installation is complete, click "Finish" to exit the Installer.
  - f. Upon successful installation, a "currently connected" status will appear in the "Site Connectivity Settings".
  - g. The Agendia Service Connector is now ready for use.

#### **CUSTOMIZING ADAPT-CE REPORTS**

Adding your organization's logo to reports.

- 1. Log into ADAPT-CE at https://ica.illumina.com/ADAPT-CE
- 2. Click "Settings" in the top menu bar.
- **3.** In the section titled "Report Settings", click "Choose File" and navigate to the file location of your business logo.
  - a. Logo formats must be: JPEG, GIF, BMP or PNG.
  - b. Your logo file cannot be larger than 5 megabytes (MB).
- **4.** Click "Upload".
- **5.** Once your logo is uploaded, it will be included in the upper right corner of each report you generate.

Adding an "Authorized Signature" box to Technical Reports.

- 6. Log into ADAPT-CE at https://ica.illumina.com/ADAPT-CE
- 7. Click "Settings" in the top menu bar.
- **8.** In the section titled "Report Settings", click the "Include signature box"check box. The signature box will appear in the lower left section of the Technical Report.



#### AGENDIA

Available Codes	Dashboard	
Active Uploads	STATUS	SAMPLE
Active opioads	~	~
Sample6_S6_L001_R1_001.fastq.gz		Sample5_S5_L001_R1_001
		5 Sample2_S2_L001_R1_001
		Sample3_S3_L001_R1_001
C		Sample4_S4_L001_R1_001
		Sample1_S1_L001_R1_001

# Using ADAPT-CE

- **CAUTION:** To ensure the privacy of your patients, do not include any personally identifying information (PII) in the filenames of your FASTQ files.
- CAUTION: The filenames must only contain alphanumeric characters (0-9, a-z, A-Z), and underscore characters (\_). File extension must be in lowercased ".fastq.gz" format. E.g., "AbC\_123.fastq.gz"
- CAUTION: DO NOT alter the contents of your FASTQ files.Doing so may cause incorrect results to be generated or may prevent ADAPT-CE from processing.
  - 1. When ready for uploading, copy the FASTQ file(s) into the directory specified during step 6 of "Installing the Agendia Service Connector".
    - a. If you do not see file extensions in your file browser, please contact your IT Department for assistance.
  - **2.** The Agendia Service Connector will detect when new FASTQ are present and automatically upload them to ADAPT-CE.
  - 3. Log into ADAPT-CE at https://ica.illumina.com/ADAPT-CE
  - 4. Ongoing uploads are shown on the "Active Uploads" page in ADAPT-CE.
  - 5. Upon a successful upload, the FASTQ will appear on the Dashboard.
  - 6. FASTQs can now be analyzed and generate reports.





### **Analyzing Data**

- 1. Log into ADAPT-CE at https://ica.illumina.com/ADAPT-CE
- 2. Click "Dashboard" in the top menu bar.
- **3.** Select FASTQ file(s) you want to analyze by clicking the respective check boxes on the same row as the Sample.
- 4. Click "Analyze".
- 5. You will be prompted to enter the "Pipeline" and "Activation code" to set up the analysis settings.
- A a. CAUTION: Make sure that the Available Codes you select has sufficient remaining reactions for your planned Analysis. If you have insufficient reactions for your planned analysis, you will need to split your batch to conform with remaining kit codes.
- **6.** Once you have confirmed the entries, click "Analyze" to start analysis of the FASTQs.
- 7. During data analysis, the status field next to the relevant FASTQ files will show as "processing".
- **8.** Upon completion of data analysis, the status field next to the relevant FASTQ files will change to "succeeded".

### **Downloading Reports**

- 1. Log into ADAPT-CE at https://ica.illumina.com/ADAPT-CE
- 2. Click on "Dashboard" in the top menu bar.
- **3.** To print reports:
  - a. Click the check box next to the file(s) and click "Print".
  - b. Your PDF reader software will open the selected file(s).
  - c. The Technical Report and Explanation of Results reports can now be printed.
- 4. To save reports:
  - a. Click the check box next to the file(s) and click "Save as PDF".
  - b. Your PDF reader software will open the selected file(s).
  - c. Save the reports to a directory of your choice.

SPECIMEN FILE ID: Sampl	e1_S1_L001_R1_001		
			FOR TESTING LAB USE
Run Information			
	Instrument	Date of Data	Date of Report
Samples in Run	Serial Number	Submission	Generation
10	@MISEQ	28-Aug-2020 18:05:44 UTC	28-Aug-2020 18:28:23 UTC
Human Assemb	y Version	RPrint Version	QC Model Version
GRCh37 (h	1	v1.40	v3.1
GR0a37 (H	1159	v140	v3.1
GR0a37 (N Detailed QC Information	119)	v1.40 BluePrint: Luminal-t	v3.1 ype
GR0a3 (k) Detailed QC Information	119)	v1.40 BluePrint: Luminal-t	v3.1 ype
GRGA37 (H Detailed QC Information	199	V140	v3.1 ype
GRGA37 (H Detailed QC Information	1159	UI.40 BluePrint: Luminal-t	v3.1
GRGA37 (H Detailed QC Information Test Results MammaPrint: Low Risk	1159 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	V1.4.0 BluePrint: Luminal-t Luminat HEIR2 -1098 Basat	v3.1
GR037 (N Detailed QC Information Test Results MammaPrint: Low Risk	115) 1 0 0.19	V1.40 BluePrint: Luminal-t HER2 HER2 +10% Basal +4	v3.1
GRGA37 (N Detailed QC Information Test Results MammaPrint: Low Risk 4.1 5.1775 anyte Standard 1011 (1)	110)	V1.40 BluePrint: Luminal-t HET2 HET2 +098 Basat +4	v2.1 ypo 0.55 0
GRGA37 (N Detailed QC Information Test Results MammaPrint: Low Risk 4 4.1 5.1775 anys to any 10 any	110)	V1.40 BluePrint: Luminal-t Luminat HET2 -109 Basat 4.4	v3.1

### **ADAPT-CE** Reports

ADAPT-CE generates two reports:

- I. Technical Report
- 2. Explanation of Results

Reports are combined in a single PDF file for your convenience. Sample reports can be found on our website: www.agendia.com/diagnostic-products/resources.html

### **Technical Report**

The Technical Report contains the following sections:

- 1. Specimen File ID
- 2. Testing Lab Use Only
- 3. Run Information
- 4. Detailed QC Information
- 5. MammaPrint Test Result
- 6. BluePrint Test Result

#### **1. SPECIMEN FILE ID**

▲ CAUTION: Users are responsible for ensuring that all uploaded files are deidentified. The Specimen File ID is the name of the FASTQ file that was analyzed to generate the Technical Report. To ensure the privacy of your patients DO NOT include any personal identifiable information (PII) in your FASTQ file name, ADAPT-CE will not match the Specimen File ID to any other information.

#### 2. TESTING LAB USE ONLY

This section is intended for the lab to use after they download the document in the case that they would like to add any additional information to the report.

			FORTESTING	LAB USE ON
Run Information	Instrument	Data of D	ata Data	of Poport
Samplas in Run	Serial Number	Submice	ion Ga	or Report peration
10	@MISEQ	28-Aug-202 18:05:44 U	10 28-A	ug-2020
Human Assembly Ve	ersion	<b>RPrint Version</b>	QC Model	Version
GRCh37 (hg19)		v1.4.0	v3.	1
Detailed QC Information				
	QC Metric		Value	Verdict
Tota	l Read Counts (log <sub>2</sub> )		20.904	Pass
1	Percent Mapped		93%	Pass
P	ercent On Target		81%	Pass
	Percent Q30		96%	Pass
Additional N	GS Run Quality Assessm	ient		Pass
Mammał	rint Quality Assessment			Pass
BluePri	nt Quality Assessment			Pass
0	verall Assessment			Pass
Test Results MammaPrint: Low Risk		BluePrint: Lum	inal-type	
Walling The Low Risk		Luminal:	inter-type	÷.
				0.85
+		HER2:		
0.	9	-1.09	8	
		Basal: +	-0.329	+
£-1 0	21	£-1	0	21
If a PFPE sample's MammaPrint index (0.7.) fails with classification current between -0.0575 and +0.0575, then 90%.	hir a pre-defined area around the he classification accuracy is less			
Authorized Signature				0
				(0)
			A	GENDI
				PRELISION ONCOLO

#### 3. RUN INFORMATION

This section contains information about the analysis performed by ADAPT-CE. The table below provides additional details:

Run Information	Details
Samples in Run	The number of samples in an analysis run
Instrument Serial Number	The serial number of the MiSeq instrument
Date of Data Submission	Date FASTQs are detected and uploaded
Date of Report Generation	Date the reports are analyzed
Human Assembly Version	The version of the human genome used to map the NGS reads.
RPrint Version	The version of the RPrint component of ADAPT-CE
QC Model Version	The version of the QC model within RPrint

#### 4. DETAILED QC INFORMATION

This section contains various quality control (QC) metrics within an individual sample's analysis results. The Total Read Counts, Percent Mapped, Percent On Target and Percent Q30 are commonly used in analysis of RNA sequencing data. The other QC metrics are proprietary to Agendia and are part of the algorithm component of ADAPT-CE.

Note: If any of the above-mentioned QC metrics fail,

- Overall Assessment will display a "Fail" verdict.
- Test Results section: "Unable to provide result for this specimen"
- Explanation of Results will not be provided.

			FORTESTING	G LAB USE ONLY
Run Information	In street and		D-4-	-60
Samples in Run	Serial Number	Submission	Gate	eneration
10	@MISEQ	28-Aug-2020	28-	Aug-2020
Uuman Assemblu	Version	18:05:44 UTC	18: OC Mode	28:23 UTC
Human Assembly	Version	RPrint version	QC Mode	i version
GRCh37 (hg1	4)	V1.4.0	V3	.1
etailed QC Information				
	QC Metric		Value	Verdict
To	tal Read Counts (log <sub>2</sub> )		20.904	Pass
	Percent Mapped		93%	Pass
	Percent On Target		81%	Pass
Ashilatana	Percent Q30		90%	Pass
Additiona	Print Quality Assessme	nt		Pass
Blue	Print Quality Assessment			Pass
	Overall Assessment			Pass
'est Results JammaPrint: Low Risk		BluePrint: Lumina	al-type	
		Luminal:		
				0.85
+ +	<b>+</b> +	HER2:		+
	0.19	-1.098	÷ .	
		Basal:	-0.329	
x -1 0	21	± -1	0	21
a FFFE sample's MammaPrint Index (BP) fails assistation cut-off between -0.0575 and +0.057 an 90%.	vible a pre-defined area around the 5, the classification accuracy is less			
Authorized Signature				2
				AGENDIA
				NULINDIA

#### 5. MAMMAPRINT TEST RESULT

The MammaPrint result is provided as a binary result of either "Low Risk" or "High Risk" for risk of recurrence. The prognostic profile (Low Risk, High Risk) of the sample is determined by calculating the MammaPrint Index (MPI) on a scale of -1.000 to +1.000

- High Risk results are those results that are equal to or below 0.000
- Low Risk results are those above 0.000

If the MammaPrint Index (MPI) falls within a pre-defined area around the classification cut-off between -0.058 and +0.058, the classification accuracy is less than 90%.

#### 6. BLUEPRINT TEST RESULT

The BluePrint result is provided as Luminal-type, HER2-type, or Basaltype. Under the BluePrint outcome are graphic scales indicating the BluePrint indices (one for each of the three subtypes), ranging from -1.000 to +1.000

• The subtype with the highest value is the dominant subtype and hence is the outcome of BluePrint. In the case of multiple dominant subtypes, the result will display: "Mixed subtype".



### Explanation of Results (EoR)

The Explanation of Results is provided as a tool to supplement the results provided in the Technical Report described above. The Explanation of Results explains the MammaPrint and BluePrint results in the context of published clinical data.

Furthermore, the integration of clinical risk assessment with MammaPrint results can help refine an individual's prognosis to help better guide the most appropriate treatment management strategy. The percentage of patients without distant recurrence at 5 years (DMFS) shown in the diagrams in sections 5 and 6 of the EoR were observed in the MINDACT trial<sup>3,6</sup>.

The EoR is a two-page document that contains the following key sections:

- 1. Specimen File ID
- 2. Summary of Individual Test Results
- 3. Predicted Result without Systemic Treatment
- 4. Data from the MINDACT Trial for Concordant Classification
- 5. Data from the MINDACT Trial for Discordant Classification

not match the Specimen File ID to any other information.

- 6. Clinical Risk Assessment Table
- 7. BluePrint Molecular Subtyping Results

#### **1. SPECIMEN FILE ID**

CAUTION: Users are responsible for ensuring that all uploaded files are de-identified. The Specimen File ID is the name of the FASTQ file that was analyzed to generate the Technical Report. To ensure the privacy of your patients DO NOT include any PI in your FASTQ file name. ADAPT-CE will



#### 2. SUMMARY OF INDIVIDUAL TEST RESULTS

This section summarizes the MammaPrint and BluePrint result from the Technical Report

- MammaPrint Risk of Recurrence Result
- MammaPrint Index
- Average 10-year risk of recurrence for lymph node negative (LN0) patients with the same risk result if they received no endocrine therapy or chemotherapy<sup>1</sup> (untreated).
- BluePrint Molecular Subtype Result

#### 3. PREDICTED RESULT WITHOUT SYSTEMIC TREATMENT

This section provides the predicted average risk of recurrence without adjuvant treatment at 5 and 10 years, with 95% confidence intervals shaded in light green.

#### 4. DATA FROM THE MINDACT TRIAL FOR CONCORDANT CLASSIFICATION WITH SYSTEMIC TREATMENT

This section provides the percentage of patients without metastasis at 5-years (Distant Metastasis Free Survival endpoint) with concordant classification (Clinically High and MammaPrint High Risk or Clinically Low and MammaPrint Low Risk).

- For patients with a MammaPrint Low Risk result, this section provides the percentage of patients without metastasis at 5-years that had Endocrine Therapy alone that were classified as Clinically Low Risk and MammaPrint Low Risk<sup>3</sup>.
- For patients with a MammaPrint High Risk result, this section provides the percentage of patients without metastasis at 5-years that had Endocrine Therapy and Chemotherapy that were classified as Clinically High Risk and MammaPrint High Risk<sup>3</sup>.

## 5. DATA FROM THE MINDACT TRIAL FOR DISCORDANT CLASSIFICATION

This section shows the percentage of patients without metastasis at 5years (Distant Metastasis Free Survival endpoint) with discordant classification (Clinically High and MammaPrint Low Risk or Clinically Low and MammaPrint High Risk).

		Gade	Nodal Status	Tumor Size	Cipical Risk in MIND
	TRIPL SHOULD	Ciede	NOLE SEED	< 3 m	low
		Well differ on Exted	Node-negative	3.1.5cm	High
		(Grade 1)		< 2cm	Low
	avi.		1-3 positive nodes	2.1-5cm	High
	at	Moderately		≤ 2cm	Low
	2	differ en trated	Node-n eg ative	2.1-5cm	High
	HE	(Grade 2)	1-3 positive nodes	Any size	High
e.		Poorly differentiated	Node a section	≤ 1cm	Low
osit		or undifferentiated	Nuberiney acive	1.1-5cm	High
6		(Grade 3)	1-3 positive nodes	Any size	High
		Well differ en tiated	Note-net ative	< 2cm	Low
		Moderately		2.1-5cm	High
	stiv	(Grade 1 / Grade 2)	1-3 positive nodes	Any size	High
	od a	(		≤ icm	Low
	TER.	Poorly differentiated	Node-n eg ative	1.1-5cm	High
	Ŧ	or undifferentiated (Grade 3)	1-3 positive nodes	Any size	High
				≤ 2cm	Low
	2	Well differ en tiated	Node-n eg ative	2.1-5cm	High
	100	(Grade 1)	1-3 positive nodes	Any size	High
	8	Moderately		≤ 1cm	Low
	ER2	differentiated or poorly differentiated	Node-n eg ative	1.1-5cm	High
	-	or undifferentiated (Grade 2 /	1-3 positive nodes	Any size	High
stive		Grade 3) Woll differ on Exted		,	
26 July		or	Node-n eg ative	s icm	Low
ER	9	Moderately differentiated		1.1-5CM	High
	i i i i i i i i i i i i i i i i i i i	(Grade 1 / Grade 2)	1-3 positive nodes	Any size	High
	8	Poorly differentiated			
	Ë	or undifferentiated (Grade 3)	Any	Any size	High
Survival Strati	fied by BluePrint	Molecular Tumor Su	btyping <sup>2</sup>	100	
Survival Strati Breast cancer is a heterop enables more informed to BluePrint is a functional on HER2-type and Basal-typ molecular subtypes: 24,5 Combining MammaPrint : Luminal-Type/Ma Uminal-Type/Ma	fied by BluePrint geneous disease and the group reatment decision-making. notocular subplying assay that is a solution of the mRNA I and BluePrint allows patients to ammaPrint Low Risk (Luminal ammaPrint High Risk (Luminal	Molecular Tumor Su ing of breast cancers into distinct cill base/lise breast cancer into three dist wells of 80 genes that best discrimin is be stratified into the following subp 3)	btyping <sup>2</sup> hiałly-relevant subtypes anct subtypes: Luminal-type, nate among the following groups:	10- 30- 30- 40- - (artes)-40-	and the second
Survival Strati Breat cancer is a heterog enables more informed to BluePrint is a functional HER2-type and Basal- typ molecular subtypes: 24.5 Combining MammaPrints - e Luminal-Type/M = Luminal-Type/M = Basal-Type	field by BluePrint precess disease and the group reatment decision making, indexular subhyping assay that is by determining the mRNA I and BluePrint allows patients to ammaPrint Low Risk (Luminal ammaPrint High Risk (Luminal	Molecular Tumor Su ing of breast cancers into distinct of lassifies breast cancer into three dist views of 80 genes that best discrimin is be strattified into the following subp 3)	btyping? nically-relevant subtypes dict subtypes: Luminal-type, nate among the following groups:	10- 50- 50- 50- 50- 50- 50- 50- 50- 50- 5	and a second
Survival Strati Breat cancer is a heterop Budyini is a functional Budyini is a functional HER2-type and Basal-type melicular subtypes: 24-74 Combini on Manamayini a Combini on Manamayini a Luminal-TypeNt I EBRAType Basal-Type	fied by BluePrint precess disease and the group reatment decision -making, indecular subtyping assay that e by determining the mBNA i and BluePrint allows patients to antmaPrint Low Risk (Luminal ammaPrint High Risk (Luminal	Molecular Tumor Su ing of breast cancer into three dist was files breast cancer into three dist was dr by generation with the start distribu- tion be stratified into the following subp 3) Chemosensibility Relevance <sup>2</sup>	btyping? nically-relevant subtypes dnct subtypes: Luminal-type, nate among the following groups:	0- 0- 0- 0- 0- 0- 0- 0- 0- 0-	
Survival Strati Breat cancer is a heteror BuePrint is a functional the BuePrint is a functional the HER2-type and Basale kyp molecular subtypes? 1.47.4 Combin ing MaximanaPrint a Combin ing MaximanaPrint a Combin ing MaximanaPrint a Laminal-Type/Hr. Basal-Type Basale Type Low Risk Luminal-Type (	fied by BluePrint protects disease and the group catenand decision making. Indecular subspling acray that is an abl subvinit allows patients to annuBrint Low Risk (Luminal annuPrint High Risk (Luminal A)	Molecular Tumor Su and of breast cancers into detarct of the software transmission of the software of the breast startified into the following subp and Chemosensibility Relevance <sup>2</sup> Low Wathood of pathologic col	btyping <sup>2</sup> hically-relevant subtypes hically-relevant subtypes hate among the following proups: mplete response (pCR) (Ø%)	10 00 00 00 00 00 00 00 00 00	
Survival Strati Bread: cancer is a hatero maleis. more informed b Bruedric tas a functional m HER2-type and Basal-type Manual Stratistics Combining MammaPrit t Luminal-Type/ML Black Type Babty pe Low Risk Luminal-Type (1 High Risk Luminal-Type (1	fied by BluePrint geneeus (assate and the group adamt decision walking, underwise autohypiking actary that to by a dearmining the mitNAL A and Blu divinit a lows patients to ammaPrint High Risk (Luminal A) (B)	Molecular Tumor Su ing of breast cancers into distinct of buscliffs breast cancer iso three data buscliffs breast cancer iso three data buscliffs breast cancer iso the data Chemosensibility Relaxance <sup>2</sup> Low Bustithood of pathologic co Improved pCR compared to Ling	btyping <sup>2</sup> hicklip-relevant subtypes hicklip-relevant subtypes hicklip-r	10 10 10 10 10 10 10 10 10 10	in in in
Survival Stratt Brast cancer is a hetero makes more informed budyets is a hetero metal-stype and Basal-type metal-stype and examination of the example and the example budyet budyet Hetero Hetero Hetero Hetero Hetero	fied by BluePrint geneous disease and the group calamet decision waking. Index use subspiring access that be a subspiring access that be another than the subspiring access that a more than the subspiring access that a more subspiring access to a subspiring access to a subspiring access to a subspiring access to a subspiring access to a subspiring access to a subspiring access to a subspiring access to a subspiring access to a subspiring access to a subspiring access to a subspiring access to a subspiring access to a subspiring	Molecular Tumor Su reg of beaut canons sho district of the second second second second second second second second second second second second second Chemosensibly, Relevance <sup>2</sup> Lew Mailmont of pathologic co Improved pCR compared to Lui pCR 47%	btyping? hickly-relevant subtypes hick subtypes: Luminal-type, hate among the following proups: mplete response (pCR) (0%) rinal A (10% vs 0%)	10 10 10 10 10 10 10 10 10 10	20 40 20 Lucito tura to statisfication by
Survival Strati Breat cancer is a heteror mables more informed to mables more informed to the strategy of the strategy HER2 type and Basal-type - East-Type - Basal-Type - Basal-Type - Basal-Type - Subtype Lever Mas.Luminal-Type (L	fied by BluePrint geneous ideases and the group calend deals weathing deals weathing related are subspiring access that a be yeld externing the mRNA 1 and BL dPrint allows patients th anomaPrint Low Rak (Luminal mmaPrint High Rak (Luminal A)	Molecular Tumor Su mig of breast cancers into distinct dia lassifies breast cancer into three dist west of Big groups that best discrimin- te best atflifed into the following subp )) Chemosensitivity Relevance <sup>2</sup> Low Healthood of pathogic co temperator for conservations	btyping? hickly-relevant subtypes hick subtypes: Luminal-type, hate among the following proups: mplete response (pCR) (0%) mplete response (pCR) (0%)	10 44 42 42 42 42 42 44 42 44 44	

For patients with a MammaPrint Low Risk result, this section provides the percentage of patients without metastasis at 5-years that had Endocrine Therapy alone compared to those that received Endocrine Therapy and Chemotherapy that were classified as Clinically High Risk and MammaPrint Low Risk in the MINDACT Study<sup>3,6</sup>.

For patients with a MammaPrint High Risk result, this section provides the percentage of patients without metastasis at 5-years that had Endocrine Therapy alone compared to those, that received Endocrine Therapy and Chemotherapy that were classified as Clinically Low Risk and MammaPrint High Risk in the MINDACT Study<sup>3,6</sup>.

**Note:** No sub-analysis has been performed on individual molecular subtypes. The data refers to the randomized cohort which includes all molecular subtypes. There is no adequate data to support treatment of MammaPrint Low Risk Basal-type tumors or MammaPrint Low Risk HER2-Type with endocrine therapy alone.

#### 6. CLINICAL RISK ASSESSMENT TABLE

As referenced in the supplementary material of the MINDACT publication (see Figure 12), this table can help determine the clinical risk results as defined in the MINDACT trial (Clinically High or Low Risk)<sup>3,6</sup>. Clinical risk classification in MINDACT was carried out using the modified version of Adjuvant! Online (version 8.0)<sup>3,6</sup>.

#### 7. BLUEPRINT MOLECULAR SUBTYPING RESULTS

This section provides results of study showing chemosensitivity for patients in a neoadjuvant setting based on molecular subtype <sup>2,4,5</sup>.

### Troubleshooting

- The following Troubleshooting points pertain to topics related to ADAPT-CE setup and operation.
- For an additional list of troubleshooting topics, please refer to the 😵 Help tab at the top right of the ADAPT-CE Interface.

Problem	Solution
Forgot your password to ADAPT-CE.	Go to the login screen from <u>https://ica.illumina.com/ADAPT-CE</u> . Click on the "Forgot password?" link and follow the instructions provided. If you still are unable to login, contact NGS.support@agendia.com for additional assistance.
Experiencing issues with setting up the Agendia Service Connector.	Go to the "Settings" section of ADAPT-CE and click "Delete" on the connector you are having issues with. Ensure a local folder on the computer is established and follow steps to install another uniquely named connector.
Files are not being uploaded to ADAPT-CE via the Agendia Service Connector.	Go to the "Settings" section of ADAPT-CE and ensure that the "Local folder" listed for the Agendia Service Connector matches the directory where the FASTQ files are.
Pages in ADAPT-CE are not functioning as expected.	Click the "Refresh" button 🖸 on the page. If the problem persists, contact NGS.support@agendia.com.
Duplicate FASTQ files appear within ADAPT-CE	Make sure that you upload your FASTQ file only once when using the Agendia Secure Connector. In the event you duplicate an upload, navigate to the Agendia Secure Connector upload folder, delete the duplicates and reupload a single file.
The result for a sample only includes a Technical Report and does not include an Explanation of Results (EoR) document.	Check the verdict for the Overall Assessment. If it says "Fail", then no Explanation of Results (EoR) is generated for the sample.
You are unable to print or save reports for a sample.	Ensure that the status field next to the sample on the "Dashboard" page says "succeeded" and that a PDF icon is shown 🖾
FASTQ files remain hanging underneath "Active Uploads" after deleting the FASTQ file from the connector or after successful FASTQ file upload into the Dashboard.	Click the "Abort Data Transfer Functionality" button <sup>©</sup> within "Active Uploads" for the hanging FASTQ file that you wish to remove.



### **Miscellaneous**

#### SECURITY

Agendia has established a Privacy Policy and Terms of Service available on our website at <u>www.agendia.com</u> to inform you of the specific practices and guidelines that help ensure the security and confidentiality of personal information that you may provide.

By using or accessing the Site, including the Agendia Service Connector, or by transmitting information through the Agendia Service Connector, you agree to the terms of our Privacy Policy and Terms of Service. If you do not agree with the terms of the Privacy Policy and Terms of Service or future terms, do not access or use (or continue to access) the Site or transmit information through the Agendia Service Connector. Your continued use of the Site and the Agendia Service Connector, even after we may have posted updates to our Privacy Policy and Terms of Service, constitutes your acceptance of such use.

#### **BROWSER SESSION TIMEOUT AND SYMBOLS**

For security purposes, after 15 minutes of inactivity in the browser, the software will automatically end your session and sign you out. A warning message will be displayed prior to signing you out, giving you the option to stay signed in.



**Description of Symbol** 

Indicates the medical device manufacturer, as defined in EU Directives 90/385/EEC, 93/42/EEC and 98/79/EC.

Indicates the need for the user to consult the instructions for use for important cautionary information such as warnings and precautions that cannot, for a variety of reasons, be presented on the medical device itself.

Indicates a medical device that is intended to be used as an in vitro diagnostic medical device.



If you have any questions regarding this product, please contact NGS.Support@agendia.com or by telephone at +31 (0) 20 462 1510, Monday to Friday from 08:30 to 17:00 (GMT/UTC +1).

### References

- 1. Buyse, et al. J Natl Cancer Inst. 2006 Sep 6.98(17): 1183-92
- 2. Glück S, et al. Breast Cancer Res Treat. 2013 Jun;139(3):759-67
- 3. Cardoso, F et al. N. Engl J Med. 2016 Aug 25, 375 (8): 717-29
- 4. Whitworth P, et al. Ann Surg Oncol. (2017) 24:669-675
- 5. Whitworth P, et al. Ann Surg Oncol. 2014 Oct;21(10):3261-7
- 6. Piccart M, et al. Lancet Oncol. 2021 Apr;22(4):476-488

Version Number and Date of Issuance EM-002-v4 (2023 December)



Agendia NV Radarweg 60 1043 NT Amsterdam The Netherlands

CE



#### © 2023 Agendia. All rights reserved.

Agendia®, MammaPrint®, and BluePrint® are trademarks of Agendia NV and/or its affiliate in the United States. All other names and other trademarks are the property of their respective owners. The instructions in this document must be strictly followed by qualified and properly trained personnel to ensure the proper and safe use of the product described herein.

FAILURE TO COMPLETELY READ AND EXPLICITLY FOLLOW ALL OF THE INSTRUCTIONS CONTAINED HEREIN MAY RESULT IN DAMAGE TO THE PRODUCT, INJURY TO PERSONS, INCLUDING TO USERS OR OTHERS. AGENDIA DOES NOT ASSUME ANY LIABILITY ARISING OUT OF THE IMPROPER USE OF THE PRODUCT(S) DESCRIBED HEREIN (INCLUDING PARTS THEREOF OR SOFTWARE).